Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyro… Read more
Exelixis Inc (EXEL) - Total Assets
Latest total assets as of December 2025: $2.84 Billion USD
Based on the latest financial reports, Exelixis Inc (EXEL) holds total assets worth $2.84 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Exelixis Inc - Total Assets Trend (1998–2025)
This chart illustrates how Exelixis Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Exelixis Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Exelixis Inc's total assets of $2.84 Billion consist of 50.7% current assets and 49.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.0% |
| Accounts Receivable | $286.92 Million | 10.1% |
| Inventory | $21.69 Million | 0.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $63.68 Million | 2.2% |
Asset Composition Trend (1998–2025)
This chart illustrates how Exelixis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Exelixis Inc's current assets represent 50.7% of total assets in 2025, an increase from 0.0% in 1998.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Exelixis Inc Competitors by Total Assets
Key competitors of Exelixis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Exelixis Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Exelixis Inc generates 0.82x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Exelixis Inc generates $ 27.51 in net profit.
Exelixis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.56 | 3.63 | 6.72 |
| Quick Ratio | 3.50 | 3.58 | 6.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.04 Billion | $ 1.06 Billion | $ 1.22 Billion |
Exelixis Inc - Advanced Valuation Insights
This section examines the relationship between Exelixis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.99 |
| Latest Market Cap to Assets Ratio | 3.10 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | $2.84 Billion |
| Market Capitalization | $8.82 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Exelixis Inc's assets at a significant premium ( 3.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Exelixis Inc's assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Exelixis Inc (1998–2025)
The table below shows the annual total assets of Exelixis Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.84 Billion | -3.50% |
| 2024-12-31 | $2.95 Billion | +0.18% |
| 2023-12-31 | $2.94 Billion | -4.20% |
| 2022-12-31 | $3.07 Billion | +17.40% |
| 2021-12-31 | $2.62 Billion | +22.41% |
| 2020-12-31 | $2.14 Billion | +13.35% |
| 2019-12-31 | $1.89 Billion | +32.58% |
| 2018-12-31 | $1.42 Billion | +117.05% |
| 2017-12-31 | $655.29 Million | +9.67% |
| 2016-12-31 | $597.54 Million | +79.80% |
| 2015-12-31 | $332.34 Million | +1.34% |
| 2014-12-31 | $327.96 Million | -34.84% |
| 2013-12-31 | $503.29 Million | -30.21% |
| 2012-12-31 | $721.10 Million | +83.36% |
| 2011-12-31 | $393.26 Million | +9.00% |
| 2010-12-31 | $360.79 Million | +5.06% |
| 2009-12-31 | $343.41 Million | -14.49% |
| 2008-12-31 | $401.62 Million | -2.55% |
| 2007-12-31 | $412.12 Million | +4.22% |
| 2006-12-31 | $395.42 Million | +18.85% |
| 2005-12-31 | $332.71 Million | +14.20% |
| 2004-12-31 | $291.34 Million | -18.57% |
| 2003-12-31 | $357.79 Million | +5.51% |
| 2002-12-31 | $339.11 Million | -2.16% |
| 2001-12-31 | $346.61 Million | +69.15% |
| 2000-12-31 | $204.91 Million | +984.20% |
| 1999-12-31 | $18.90 Million | +110.44% |
| 1998-12-31 | $8.98 Million | -- |